Cura Therapeutics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 3

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 11

Cura Therapeutics General Information

Description

Developer of a next-generation drug discovery platform designed to reprogram the immune system to fight complex diseases, including metastatic cancer, age-related conditions, and pathogen infections. The company offers an AI-driven protein modeling and pathway analysis approach, combining functional assays to engineer immune fusion proteins, enabling targeted treatment of tumors and reducing the risk of systemic toxicity, ultimately improving therapeutic outcomes for patients with cancer and age-related diseases.

Contact Information

Website
www.curatherapeutics.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 40 Ruskin Street
  • Ottawa, Ontario K1Y 4W7
  • Canada
+1 (514)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
HealthTech, Life Sciences, Oncology
Corporate Office
  • 40 Ruskin Street
  • Ottawa, Ontario K1Y 4W7
  • Canada
+1 (514)

Cura Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cura Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Secondary Transaction - Private 01-Jul-2026 Completed Pre-Clinical Trials
10. Later Stage VC 16-Apr-2026 Completed Pre-Clinical Trials
9. Accelerator/Incubator 25-Nov-2025 Completed Pre-Clinical Trials
8. Accelerator/Incubator 06-Mar-2025 Completed Pre-Clinical Trials
7. Accelerator/Incubator Completed Pre-Clinical Trials
6. Early Stage VC 10-Jul-2020 Completed Pre-Clinical Trials
5. Accelerator/Incubator 11-Jul-2019 Completed Startup
4. Accelerator/Incubator 05-Apr-2018 Completed Startup
3. Early Stage VC (Series 1) 05-May-2017 Completed Startup
2. Accelerator/Incubator 01-Jan-2017 Completed Startup
To view Cura Therapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Cura Therapeutics Patents

  • 43

    Total Documents Applications and Grants

  • Total Patents Families

  • 12

    Granted

  • 17

    Pending

  • Expiring in next 12 mo

Cura Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3210687-A1 Anti-pathogen interleukin-tgf-beta receptor fusion polypeptides Pending 17-Feb-2021
EP-4294422-A1 Anti-pathogen interleukin-tgf-beta receptor fusion polypeptides Inactive 17-Feb-2021
EP-4294422-A4 Anti-pathogen interleukin-tgf-beta receptor fusion polypeptides Inactive 17-Feb-2021
US-20220257712-A1 Anti-pathogen interleukin-tgf-beta receptor fusion polypeptides Active 17-Feb-2021
WO-2022178033-A1 Anti-pathogen interleukin-tgf-beta receptor fusion polypeptides Inactive 17-Feb-2021 A61K38/2013
To view Cura Therapeutics’s complete patent history, request access »

Cura Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cura Therapeutics Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
ACS BrightEdge Corporate Venture Capital Minority
FACIT Venture Capital Minority
Capital BioVentures Accelerator/Incubator
Ontario Bioscience Innovation Organization Not-For-Profit Venture Capital
MIT Alumni Angels of Northern California Angel Group Minority
You’re viewing 5 of 11 investors. Get the full list »

Ready to get started?

Request a free trial

Cura Therapeutics FAQs

  • When was Cura Therapeutics founded?

    Cura Therapeutics was founded in 2017.

  • Where is Cura Therapeutics headquartered?

    Cura Therapeutics is headquartered in Ottawa, Canada.

  • What is the size of Cura Therapeutics?

    Cura Therapeutics has 3 total employees.

  • What industry is Cura Therapeutics in?

    Cura Therapeutics’s primary industry is Biotechnology.

  • Is Cura Therapeutics a private or public company?

    Cura Therapeutics is a Private company.

  • What is Cura Therapeutics’s current revenue?

    The current revenue for Cura Therapeutics is .

  • How much funding has Cura Therapeutics raised over time?

    Cura Therapeutics has raised $1.77M.

  • Who are Cura Therapeutics’s investors?

    ACS BrightEdge, FACIT, Capital BioVentures, Ontario Bioscience Innovation Organization, and MIT Alumni Angels of Northern California are 5 of 11 investors who have invested in Cura Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process